Optimizing Cryopreservation For Leukapheresis: Advancing Cell And Gene Therapy Supply Chains

Managing the supply chain for fresh leukapheresis—an essential component in cell and gene therapy (CGT)—remains one of the most difficult challenges in the field. Because leukapheresis must be sourced from donors and quickly processed under tightly controlled conditions, the process allows little margin for error. These constraints increase the risk of variability, which can negatively affect the accuracy and outcome of CGT products. To help mitigate these issues, Alexandre Michaux, Process Development and MSAT Manager at IntegriCell, unveiled a new approach to managing leukapheresis —a method of automated cryopreservation designed to enhance CGT operational efficiency.

Cryopreservation extends the usable life of cells, reduces time-sensitive logistical challenges, and allows for better alignment with manufacturing schedules.

This advancement represents a pivotal evolution in managing leukapheresis, opening the door to greater reliability and global accessibility for CGTs. Learn more about how this innovation is shaping the next generation of cell therapy production.